312 related articles for article (PubMed ID: 31335570)
1. Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial.
Bradley JS; Roilides E; Broadhurst H; Cheng K; Huang LM; MasCasullo V; Newell P; Stone GG; Tawadrous M; Wajsbrot D; Yates K; Gardner A
Pediatr Infect Dis J; 2019 Sep; 38(9):920-928. PubMed ID: 31335570
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
Bradley JS; Broadhurst H; Cheng K; Mendez M; Newell P; Prchlik M; Stone GG; Talley AK; Tawadrous M; Wajsbrot D; Yates K; Zuzova A; Gardner A
Pediatr Infect Dis J; 2019 Aug; 38(8):816-824. PubMed ID: 31306396
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.
Vazquez JA; González Patzán LD; Stricklin D; Duttaroy DD; Kreidly Z; Lipka J; Sable C
Curr Med Res Opin; 2012 Dec; 28(12):1921-31. PubMed ID: 23145859
[TBL] [Abstract][Full Text] [Related]
4. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
Wagenlehner FM; Sobel JD; Newell P; Armstrong J; Huang X; Stone GG; Yates K; Gasink LB
Clin Infect Dis; 2016 Sep; 63(6):754-762. PubMed ID: 27313268
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
6. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
Cheng K; Newell P; Chow JW; Broadhurst H; Wilson D; Yates K; Wardman A
Drug Saf; 2020 Aug; 43(8):751-766. PubMed ID: 32602065
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
Lucasti C; Popescu I; Ramesh MK; Lipka J; Sable C
J Antimicrob Chemother; 2013 May; 68(5):1183-92. PubMed ID: 23391714
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.
Merdjan H; Rangaraju M; Tarral A
Clin Drug Investig; 2015 May; 35(5):307-17. PubMed ID: 25813217
[TBL] [Abstract][Full Text] [Related]
11. Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
Das S; Li J; Riccobene T; Carrothers TJ; Newell P; Melnick D; Critchley IA; Stone GG; Nichols WW
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670413
[TBL] [Abstract][Full Text] [Related]
12. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Franzese RC; McFadyen L; Watson KJ; Riccobene T; Carrothers TJ; Vourvahis M; Chan PLS; Raber S; Bradley JS; Lovern M
Clin Pharmacol Ther; 2022 Mar; 111(3):635-645. PubMed ID: 34687548
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
Stone GG; Bradford PA; Yates K; Newell P
J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Mazuski JE; Gasink LB; Armstrong J; Broadhurst H; Stone GG; Rank D; Llorens L; Newell P; Pachl J
Clin Infect Dis; 2016 Jun; 62(11):1380-1389. PubMed ID: 26962078
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
Torres A; Wible M; Tawadrous M; Irani P; Stone GG; Quintana A; Debabov D; Burroughs M; Bradford PA; Kollef M
J Antimicrob Chemother; 2023 Nov; 78(11):2672-2682. PubMed ID: 37700689
[TBL] [Abstract][Full Text] [Related]
17. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
Das S; Armstrong J; Mathews D; Li J; Edeki T
J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
[TBL] [Abstract][Full Text] [Related]
18. Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
Int J Antimicrob Agents; 2018 Aug; 52(2):287-292. PubMed ID: 29654893
[TBL] [Abstract][Full Text] [Related]
19. Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.
Li J; Lovern M; Riccobene T; Carrothers TJ; Newell P; Das S; Talley AK; Tawadrous M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015049
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.
Bradley JS; Armstrong J; Arrieta A; Bishai R; Das S; Delair S; Edeki T; Holmes WC; Li J; Moffett KS; Mukundan D; Perez N; Romero JR; Speicher D; Sullivan JE; Zhou D
Antimicrob Agents Chemother; 2016 Oct; 60(10):6252-9. PubMed ID: 27503642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
